Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases
文献类型：期刊论文
| 作者 | Ou, An-te1,2,3; Zhang, Jia-xin1,4; Fang, Yue-fei1,5; Wang, Rong1,6; Tang, Xue-ping1,5; Zhao, Peng-fei1,7; Zhao, Yu-ge8; Zhang, Meng9; Huang, Yong-zhuo1,2,3,10
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-11 |
| 卷号 | 42期号:11页码:1913-1920 |
| 关键词 | disulfiram lactoferrin macrophage-targeting delivery sepsis ulcerative colitis pyroptosis inflammation |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-021-00770-w |
| 文献子类 | Article |
| 英文摘要 | Sepsis is a dysregulated immune response to infection and potentially leads to life-threatening organ dysfunction, which is often seen in serious Covid-19 patients. Disulfiram (DSF), an old drug that has been used to treat alcohol addiction for decades, has recently been identified as a potent inhibitor of the gasdermin D (GSDMD)-induced pore formation that causes pyroptosis and inflammatory cytokine release. Therefore, DSF represents a promising therapeutic for the treatment of inflammatory disorders. Lactoferrin (LF) is a multifunctional glycoprotein with potent antibacterial and anti-inflammatory activities that acts by neutralizing circulating endotoxins and activating cellular responses. In addition, LF has been well exploited as a drug nanocarrier and targeting ligands. In this study, we developed a DSF-LF nanoparticulate system (DSF-LF NP) for combining the immunosuppressive activities of both DSF and LF. DSF-LF NPs could effectively block pyroptosis and inflammatory cytokine release from macrophages. Treatment with DSF-LF NPs showed remarkable therapeutic effects on lipopolysaccharide (LPS)-induced sepsis. In addition, this therapeutic strategy was also applied to treat ulcerative colitis (UC), and substantial treatment efficacy was achieved in a murine colitis model. The underlying mode of action of these DSF-LF-NPs may contribute to efficiently suppressing macrophage-mediated inflammatory responses and ameliorating the complications caused by sepsis and UC. As macrophage pyroptosis plays a pivotal role in inflammation, this safe and effective biomimetic nanomedicine may offer a versatile therapeutic strategy for treating various inflammatory diseases by repurposing DSF. |
| WOS关键词 | ULCERATIVE-COLITIS ; COLORECTAL-CANCER ; GASDERMIN D ; SEPSIS ; ACTIVATION ; PYROPTOSIS |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000698867800002 |
| 出版者 | NATURE PUBL GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309366]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Huang, Yong-zhuo |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China; 3.Chinese Acad Sci, Zhongshan Inst Drug Discovery, SIMM, Zhongshan 528437, Peoples R China; 4.Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China; 5.Guangzhou Univ Chinese Med, Artemisinin Res Ctr, Guangzhou 501450, Peoples R China; 6.Nanchang Univ, Coll Pharm, Nanchang 330006, Jiangxi, Peoples R China; 7.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China; 8.Tongji Univ, Sch Med, Shanghai 200092, Peoples R China; 9.Zhejiang Univ, Womens Hosp, Sch Med, Dept Pharm, Hangzhou 310006, Peoples R China; 10.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ou, An-te,Zhang, Jia-xin,Fang, Yue-fei,et al. Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases[J]. ACTA PHARMACOLOGICA SINICA,2021,42(11):1913-1920. |
| APA | Ou, An-te.,Zhang, Jia-xin.,Fang, Yue-fei.,Wang, Rong.,Tang, Xue-ping.,...&Huang, Yong-zhuo.(2021).Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.ACTA PHARMACOLOGICA SINICA,42(11),1913-1920. |
| MLA | Ou, An-te,et al."Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases".ACTA PHARMACOLOGICA SINICA 42.11(2021):1913-1920. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。